FoxL2 and Smad3 Coordinately Regulate Follistatin Gene Transcription*

Follistatin is a transcriptional target and a modulator of activin action. Through an autocrine/paracrine loop, activin controls follistatin levels and thus regulates its own bioavailability. In gonadotropic αT3-1 cells, activin induces follistatin transcription primarily through the action of Smad3 at an intronic Smad-binding element (SBE1). Using a proteomics approach, we searched for endogenous αT3-1 proteins that participate in SBE1-mediated transcription. We identified FoxL2, a member of the forkhead family, as a candidate modulator of SBE1 function. Mutations of FoxL2 are associated with the blepharophimosis/ptosis/epicanthus inversus syndrome characterized with craniofacial defects and premature ovarian failure. FoxL2 localizes to α-glycoprotein subunit- and follicle-stimulating hormone β-positive cells of the adult mouse pituitary and is present in αT3-1 and LβT2 cells, but its pituitary actions remain largely unknown. We have determined that FoxL2 binds to a forkhead-binding element (FKHB) located just downstream of the SBE1 site of the follistatin gene and functions as a Smad3 partner to drive SBE1-mediated transcription in αT3-1 cells treated with activin. Chromatin immunoprecipitation assays confirm that endogenous FoxL2 and Smad3 are recruited to the intronic enhancer of the follistatin gene where the SBE1 and FKHB sites are located. Exogenous FoxL2 enhances SBE1-mediated transcription, and short hairpin RNA-mediated knockdown of endogenous FoxL2 protein compromises this effect in αT3-1 cells. FoxL2 directly associates with Smad3 but not Smad2 or Smad4. This association between Smad3 and FoxL2 is mediated by the MH2 domain of Smad3 and is dependent on an intact forkhead domain in FoxL2. Altogether, these observations highlight a novel role for FoxL2 and suggest that it may function as a transcriptional regulator and a coordinator of Smad3 targets.

[1]  T. de Ravel,et al.  Identification of 34 novel and 56 known FOXL2 mutations in patients with blepharophimosis syndrome , 2008, Human mutation.

[2]  B. Benayoun,et al.  The identification and characterization of a FOXL2 response element provides insights into the pathogenesis of mutant alleles. , 2008, Human molecular genetics.

[3]  B. Benayoun,et al.  Differential functional effects of novel mutations of the transcription factor FOXL2 in BPES patients , 2008, Human mutation.

[4]  C. Stephan,et al.  Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. , 2008, Journal of proteome research.

[5]  J. Vaughan,et al.  A Smad-binding Element in Intron 1 Participates in Activin-dependent Regulation of the Follistatin Gene* , 2008, Journal of Biological Chemistry.

[6]  Kunihiro Tsuchida,et al.  Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell–Depleted SCID Mice , 2008, Clinical Cancer Research.

[7]  Jodi L. Haller,et al.  FOXL2 in the pituitary: molecular, genetic, and developmental analysis. , 2006, Molecular endocrinology.

[8]  N. H. Uhlenhaut,et al.  Foxl2 function in ovarian development. , 2006, Molecular genetics and metabolism.

[9]  A. Mukherjee,et al.  Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. , 2006, Endocrinology.

[10]  R. Veitia,et al.  FOXL2 activates P450 aromatase gene transcription: towards a better characterization of the early steps of mammalian ovarian development. , 2006, Journal of molecular endocrinology.

[11]  C. Robinson,et al.  Structural basis for the inhibition of activin signalling by follistatin , 2006, The EMBO journal.

[12]  I. Verma,et al.  Design and cloning of lentiviral vectors expressing small interfering RNAs , 2006, Nature Protocols.

[13]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[14]  Robert W Cook,et al.  The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. , 2005, Developmental cell.

[15]  C. Lawrence,et al.  RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. , 2005, RNA.

[16]  W. Vale,et al.  Antagonists of activin signaling: mechanisms and potential biological applications , 2005, Trends in Endocrinology & Metabolism.

[17]  Matthew E Monroe,et al.  Probability-based evaluation of peptide and protein identifications from tandem mass spectrometry and SEQUEST analysis: the human proteome. , 2005, Journal of proteome research.

[18]  D. Haisenleder,et al.  Regulation of gonadotropin subunit gene transcription. , 2004, Journal of molecular endocrinology.

[19]  C. Donaldson,et al.  Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin , 2004, Molecular and Cellular Endocrinology.

[20]  Ye Ding,et al.  Sfold web server for statistical folding and rational design of nucleic acids , 2004, Nucleic Acids Res..

[21]  D. Schlessinger,et al.  Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. , 2004, Human molecular genetics.

[22]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[23]  M. Pisarska,et al.  Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. , 2004, Endocrinology.

[24]  Katrin Anlag,et al.  The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance , 2004, Development.

[25]  P. Bates,et al.  Recognition of Phosphorylated-Smad2-Containing Complexes by a Novel Smad Interaction Motif , 2004, Molecular and Cellular Biology.

[26]  B. Ellsworth,et al.  The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein , 2003, Molecular and Cellular Endocrinology.

[27]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[28]  L. Bilezikjian,et al.  Rat anterior pituitary folliculostellate cells are targets of interleukin-1beta and a major source of intrapituitary follistatin. , 2003, Endocrinology.

[29]  R. Veitia,et al.  Evolution and expression of FOXL2 , 2002, Journal of medical genetics.

[30]  C. Welt,et al.  Activins, Inhibins, and Follistatins: From Endocrinology to Signaling. A Paradigm for the New Millennium , 2002, Experimental biology and medicine.

[31]  P. Carlsson,et al.  Forkhead transcription factors: key players in development and metabolism. , 2002, Developmental biology.

[32]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[33]  D. Haisenleder,et al.  GnRH pulse frequency modulation of gonadotropin subunit gene transcription in normal gonadotropes-assessment by primary transcript assay provides evidence for roles of GnRH and follistatin. , 2002, Endocrinology.

[34]  Jeffrey L. Wrana,et al.  Signal Transduction by the TGF-β Superfamily , 2002, Science.

[35]  J. Magaud,et al.  Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function , 2002, Oncogene.

[36]  K. Devriendt,et al.  Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype--phenotype correlation. , 2001, Human molecular genetics.

[37]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[38]  D. Schlessinger,et al.  The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome , 2001, Nature Genetics.

[39]  Xin Chen,et al.  The Role of FAST-1 and Smads in Transcriptional Regulation by Activin during Early Xenopus Embryogenesis* , 1999, The Journal of Biological Chemistry.

[40]  D. Phillips,et al.  Follistatin: A Multifunctional Regulatory Protein , 1998, Frontiers in Neuroendocrinology.

[41]  P. Hoodless,et al.  Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. , 1998, Molecular cell.

[42]  A. McMahon,et al.  Multistep signaling requirements for pituitary organogenesis in vivo. , 1998, Genes & development.

[43]  J. Massagué,et al.  Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. , 1997, Genes & development.

[44]  Minoru Watanabe,et al.  Smad4 and FAST-1 in the assembly of activin-responsive factor , 1997, Nature.

[45]  W. Vale,et al.  Receptor Serine Kinases and Signaling by Activins and Inhibins , 1997 .

[46]  D. Haisenleder,et al.  Pituitary activin receptor subtypes and follistatin gene expression in female rats: differential regulation by activin and follistatin. , 1996, Endocrinology.

[47]  A. Bradley,et al.  Multiple defects and perinatal death in mice deficient in follistatin , 1995, Nature.

[48]  N. Ling,et al.  Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. , 1993, The Journal of biological chemistry.

[49]  J. Findlay,et al.  Regulation of steady-state follistatin mRNA levels in rat granulosa cells in vitro. , 1992, Journal of molecular endocrinology.

[50]  K. Titani,et al.  Immunohistochemical localization of follistatin in rat tissues. , 1991, Endocrinologia japonica.

[51]  N. Ling,et al.  FOLLISTATIN BINDS TO BOTH ACTIVIN AND INHIBIN THROUGH THE COMMON BETA-SUBUNIT , 1991 .

[52]  K. Titani,et al.  Activin-binding protein is present in pituitary. , 1991, Endocrinology.

[53]  B. Hille,et al.  Intracellular responses to gonadotropin-releasing hormone in a clonal cell line of the gonadotrope lineage. , 1991, Molecular endocrinology.

[54]  A. Mason,et al.  Evidence for an autocrine role of activin B within rat anterior pituitary cultures. , 1991, Endocrinology.

[55]  K. Titani,et al.  Activin-binding protein from rat ovary is follistatin. , 1990, Science.

[56]  N. Ling,et al.  Follistatin gene expression in the ovary and extragonadal tissues. , 1989, Molecular endocrinology.

[57]  N. Ling,et al.  Primary structure of the human follistatin precursor and its genomic organization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[58]  H. Burger,et al.  The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. , 1987, Biochemical and biophysical research communications.

[59]  N. Ling,et al.  Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. , 1987, Molecular endocrinology.